| Medical and Health Sciences | Lifetime | 58 | BE 2 | 100.00 |
| Biological Sciences | Lifetime | 65 | BE 1 | 99.99 |
| Chemistry | Lifetime | 123 | BE 2 | 99.92 |
| Infectious Diseases | Lifetime | 1 | BE 1 | 99.99 |
| Epidemiology | Lifetime | 11 | BE 2 | 99.98 |
| Virology | Lifetime | 3 | BE 1 | 99.95 |
| Organic Chemistry | Lifetime | 73 | BE 2 | 99.89 |
| Molecular Biology | Lifetime | 199 | BE 2 | 99.91 |
| Genetics | Lifetime | 188 | BE 6 | 99.58 |
| Immunology | Lifetime | 127 | BE 1 | 99.75 |
| Medicinal and Pharmaceutical Chemistry | Lifetime | 12 | BE 1 | 99.37 |
| Oncology | Lifetime | 210 | BE 2 | 99.66 |
| Chemical Biology and Bioorganic Chemistry | Lifetime | 6 | BE 1 | 99.35 |
| Hepatology | Lifetime | 115 | BE 1 | 99.20 |
| Rheumatology | Lifetime | 988 | BE 8 | 93.95 |
| Agronomy and Crop Science | Lifetime | 766 | BE 10 | 92.63 |
| Pharmacology | Lifetime | 658 | BE 8 | 91.02 |
| Pharmaceutical Science | Lifetime | 616 | BE 7 | 86.31 |
| Ophthalmology | Lifetime | 727 | BE 4 | 83.37 |
| Physiology | Lifetime | 462 | BE 4 | 80.01 |
| Infectious Diseases | 2021-2025 | 150 | BE 3 | 97.53 |
| Virology | 2021-2025 | 11 | BE 1 | 96.17 |
| Epidemiology | 2021-2025 | 434 | BE 9 | 96.21 |
| Heterocyclic Compound Synthesis and Bioactivity | Lifetime | 1 | BE 1 | 99.97 |
| HIV/AIDS drug development and treatment | Lifetime | 1 | BE 1 | 99.99 |
| Synthesis and Biological Evaluation | Lifetime | 1 | BE 1 | 99.97 |
| Synthesis and Characterization of Heterocyclic Compounds | Lifetime | 1 | BE 1 | 99.99 |
| Biochemical and Molecular Research | Lifetime | 1 | BE 1 | 99.98 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 1 | BE 1 | 99.97 |
| HIV Research and Treatment | Lifetime | 2 | BE 1 | 99.98 |
| Cytomegalovirus and herpesvirus research | Lifetime | 2 | BE 1 | 99.98 |
| Herpesvirus Infections and Treatments | Lifetime | 2 | BE 1 | 99.97 |
| Quinazolinone synthesis and applications | Lifetime | 1 | BE 1 | 99.96 |
| Virus-based gene therapy research | Lifetime | 8 | BE 1 | 99.94 |
| Click Chemistry and Applications | Lifetime | 6 | BE 1 | 99.95 |
| T-cell and Retrovirus Studies | Lifetime | 3 | BE 1 | 99.89 |
| Hepatitis C virus research | Lifetime | 24 | BE 1 | 99.90 |
| HIV/AIDS Research and Interventions | Lifetime | 27 | BE 1 | 99.85 |
| Hepatitis B Virus Studies | Lifetime | 33 | BE 1 | 99.85 |
| Synthesis of Organic Compounds | Lifetime | 9 | BE 1 | 99.57 |
| Viral-associated cancers and disorders | Lifetime | 16 | BE 1 | 99.76 |
| Pharmacological Effects of Natural Compounds | Lifetime | 25 | BE 2 | 99.55 |
| Poxvirus research and outbreaks | Lifetime | 6 | BE 1 | 99.66 |
| Viral Infections and Immunology Research | Lifetime | 30 | BE 1 | 99.60 |
| Polyomavirus and related diseases | Lifetime | 18 | BE 1 | 99.56 |
| Synthesis and Reactions of Organic Compounds | Lifetime | 29 | BE 2 | 99.39 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 27 | BE 1 | 99.41 |
| interferon and immune responses | Lifetime | 36 | BE 2 | 99.67 |
| Carbohydrate Chemistry and Synthesis | Lifetime | 61 | BE 1 | 99.56 |
| Chemokine receptors and signaling | Lifetime | 24 | BE 2 | 99.34 |
| Immune Cell Function and Interaction | Lifetime | 216 | BE 2 | 99.72 |
| RNA Interference and Gene Delivery | Lifetime | 212 | BE 2 | 99.30 |
| Cancer therapeutics and mechanisms | Lifetime | 116 | BE 1 | 99.25 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 366 | BE 3 | 99.30 |
| Synthesis of heterocyclic compounds | Lifetime | 67 | BE 2 | 98.42 |
| Viral Infections and Vectors | Lifetime | 221 | BE 1 | 99.15 |
| Influenza Virus Research Studies | Lifetime | 159 | BE 2 | 99.08 |
| Parvovirus B19 Infection Studies | Lifetime | 67 | BE 1 | 98.88 |
| Adenosine and Purinergic Signaling | Lifetime | 120 | BE 2 | 98.07 |
| Viral Infections and Outbreaks Research | Lifetime | 113 | BE 1 | 98.71 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 212 | BE 6 | 98.62 |
| Immune Response and Inflammation | Lifetime | 458 | BE 14 | 98.83 |
| Animal Disease Management and Epidemiology | Lifetime | 247 | BE 11 | 98.47 |
| Respiratory viral infections research | Lifetime | 351 | BE 1 | 98.60 |
| DNA and Nucleic Acid Chemistry | Lifetime | 346 | BE 3 | 98.55 |
| Viral gastroenteritis research and epidemiology | Lifetime | 635 | BE 15 | 98.24 |
| Chemical Synthesis and Analysis | Lifetime | 770 | BE 8 | 98.31 |
| Synthesis and Reactivity of Heterocycles | Lifetime | 114 | BE 3 | 97.02 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 219 | BE 2 | 97.39 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 820 | BE 10 | 97.46 |
| Fluorine in Organic Chemistry | Lifetime | 366 | BE 3 | 97.88 |
| Animal Virus Infections Studies | Lifetime | 468 | BE 10 | 97.85 |
| Mosquito-borne diseases and control | Lifetime | 694 | BE 4 | 98.14 |
| Biopolymer Synthesis and Applications | Lifetime | 131 | BE 1 | 96.66 |
| Bacteriophages and microbial interactions | Lifetime | 917 | BE 16 | 97.49 |
| Phenothiazines and Benzothiazines Synthesis and Activities | Lifetime | 252 | BE 8 | 96.07 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 366 | BE 2 | 97.19 |
| Organophosphorus compounds synthesis | Lifetime | 252 | BE 2 | 96.47 |
| Virology and Viral Diseases | Lifetime | 418 | BE 6 | 96.88 |
| Phytochemical compounds biological activities | Lifetime | 227 | BE 2 | 95.99 |
| Plant Virus Research Studies | Lifetime | 881 | BE 8 | 96.46 |
| Toxoplasma gondii Research Studies | Lifetime | 321 | BE 2 | 96.31 |
| Advanced Frequency and Time Standards | Lifetime | 242 | BE 2 | 95.68 |
| Viral Infectious Diseases and Gene Expression in Insects | Lifetime | 702 | BE 9 | 95.82 |
| RNA regulation and disease | Lifetime | 649 | BE 5 | 95.20 |
| Acne and Rosacea Treatments and Effects | Lifetime | 215 | BE 6 | 95.66 |
| Eosinophilic Disorders and Syndromes | Lifetime | 865 | BE 13 | 94.47 |
| Synthesis and Reactivity of Sulfur-Containing Compounds | Lifetime | 754 | BE 11 | 93.31 |
| Fungal Plant Pathogen Control | Lifetime | 636 | BE 5 | 91.20 |
| vaccines and immunoinformatics approaches | Lifetime | 931 | BE 19 | 91.72 |
| Ferrocene Chemistry and Applications | Lifetime | 938 | BE 6 | 88.49 |
| Infectious Encephalopathies and Encephalitis | Lifetime | 923 | BE 6 | 81.42 |
| Gestational Trophoblastic Disease Studies | Lifetime | 771 | BE 9 | 81.91 |
| Synthesis and pharmacology of benzodiazepine derivatives | Lifetime | 830 | BE 8 | 78.57 |
| Biochemical and Molecular Research | 2021-2025 | 6 | BE 1 | 96.70 |
| HIV/AIDS drug development and treatment | 2021-2025 | 27 | BE 1 | 98.23 |
| HIV Research and Treatment | 2021-2025 | 49 | BE 2 | 98.34 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 83 | BE 3 | 95.02 |
| Hepatitis C virus research | 2021-2025 | 287 | BE 3 | 95.33 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 175 | BE 4 | 92.04 |
| Herpesvirus Infections and Treatments | 2021-2025 | 250 | BE 12 | 90.01 |
| Hepatitis B Virus Studies | 2021-2025 | 854 | BE 4 | 88.46 |
| Click Chemistry and Applications | 2021-2025 | 647 | BE 4 | 83.37 |
| Quinazolinone synthesis and applications | 2021-2025 | 758 | BE 7 | 57.75 |